{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T18:41:50Z","timestamp":1769884910160,"version":"3.49.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Badr University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>\n            <jats:italic>CREBBP<\/jats:italic>, <jats:italic>CEBPA<\/jats:italic>, and <jats:italic>DNMT3A<\/jats:italic> are tumor suppressor genes whose dysfunction has been reported in hematologic malignancies. Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. We aim to assess the expression level of <jats:italic>CREBBP<\/jats:italic>, <jats:italic>CEBPA<\/jats:italic>, and <jats:italic>DNMT3A<\/jats:italic> genes in an Egyptian cohort with AML. We investigated the correlation between the selected genes\u2019 mRNA levels and their association with clinical characteristics and survival. Herein, 53 adult participants diagnosed with AML were enrolled in the study. Quantitative RT-PCR was used, and computational analysis was added to analyze the relationship between the three genes. <jats:italic>CREBBP<\/jats:italic> expression influenced TLC negatively (<jats:italic>r\u00a0<\/jats:italic>= -0.328, <jats:italic>p<\/jats:italic> = 0.017). <jats:italic>DNMT3A<\/jats:italic> gene expression was found to be significantly associated with CD117 positive (<jats:italic>p<\/jats:italic>\u00a0= 0.028).\u00a0There was no significant difference between males and females in the relative <jats:italic>CREBBP<\/jats:italic>, <jats:italic>CEBPA<\/jats:italic>, and <jats:italic>DNMT3A<\/jats:italic> expression. Remarkably, AML-M3 cases were devoid of <jats:italic>CREBBP<\/jats:italic> expression. The correlation matrix of the three genes detected a significant correlation only between <jats:italic>CREBBP<\/jats:italic> and <jats:italic>CEBPA<\/jats:italic> expression (<jats:italic>r<\/jats:italic> = 0.518, <jats:italic>p<\/jats:italic> &lt; 0.0001), though the computational correlation analysis of these two genes was not significant. Our finding may suggest a complementary role of <jats:italic>CREBBP<\/jats:italic> and <jats:italic>CEBPA<\/jats:italic> in AML pathogenesis; however, further investigation on larger samples is still warranted to study the relationship of these genes with AML survival.\u00a0We are also reporting here an adult AML case with an additional chromosome 19 as the sole cytogenetic abnormality.<\/jats:p>","DOI":"10.1038\/s41598-025-93024-2","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T10:21:56Z","timestamp":1744366916000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A significant correlation exists between CREBBP and CEBPA gene expression in de Novo adult acute myeloid leukemia"],"prefix":"10.1038","volume":"15","author":[{"given":"Magda","family":"Assem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asmaa A.","family":"El Leithy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naglaa M.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed A.","family":"Al-Karmalawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Abozaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasha Mahmoud","family":"Allam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A. M.","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa","family":"Amer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gharieb S.","family":"El-Sayyad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noha H.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"issue":"3","key":"93024_CR1","first-page":"38","volume":"103","author":"A Pelcovits","year":"2020","unstructured":"Pelcovits, A. & Niroula, R. Acute myeloid leukemia: A review. Rhode Island Med. J. 103(3), 38\u201340 (2020).","journal-title":"Rhode Island Med. J."},{"key":"93024_CR2","doi-asserted-by":"publisher","first-page":"1122864","DOI":"10.3389\/fgene.2023.1122864","volume":"14","author":"M Assem","year":"2023","unstructured":"Assem, M. et al. Promoter methylation might shift the balance of Galectin-3 & 12 expression in de Novo adult acute myeloid leukemia patients. Front. Genet. 14, 1122864 (2023).","journal-title":"Front. Genet."},{"key":"93024_CR3","unstructured":"CREBBP Gene Card Page. Available from https:\/\/www.genecards.org\/cgi-bin\/carddisp.pl?gene=CREBBP&keywords=CREBBP. Accessed May 2022."},{"issue":"1\u20132","key":"93024_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ymgme.2016.06.013","volume":"119","author":"R Dutta","year":"2016","unstructured":"Dutta, R., Tiu, B. & Sakamoto, K. M. CBP\/p300 acetyltransferase activity in hematologic malignancies. Mol. Genet. Metab. 119(1\u20132), 37\u201343 (2016).","journal-title":"Mol. Genet. Metab."},{"issue":"24","key":"93024_CR5","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1128\/MCB.05830-11","volume":"31","author":"WI Chan","year":"2011","unstructured":"Chan, W. I. et al. The transcriptional coactivator Cbp regulates self-renewal and differentiation in adult hematopoietic stem cells. Mol. Cell. Biol. 31(24), 5046\u20135060 (2011).","journal-title":"Mol. Cell. Biol."},{"issue":"12","key":"93024_CR6","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/sj.leu.2400882","volume":"11","author":"R Giles","year":"1997","unstructured":"Giles, R. et al. Detection of CBP rearrangements in acute myelogenous leukemia with t (8; 16). Leukemia 11(12), 2087\u20132096 (1997).","journal-title":"Leukemia"},{"issue":"4","key":"93024_CR7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/1098-2264(200008)28:4<415::AID-GCC7>3.0.CO;2-I","volume":"28","author":"I Panagopoulos","year":"2000","unstructured":"Panagopoulos, I. et al. RT-PCR analysis of the MOZ\u2010CBP and CBP\u2010MOZ chimeric transcripts in acute myeloid leukemias with t (8; 16)(p11; p13). Genes Chromosom. Cancer 28 (4), 415\u2013424 (2000).","journal-title":"Genes Chromosom. Cancer"},{"issue":"3","key":"93024_CR8","first-page":"745","volume":"95","author":"GA Blobel","year":"2000","unstructured":"Blobel, G. A. CREB-binding protein and p300: Molecular integrators of hematopoietic transcription. Blood J. Am. Soc. Hematol. 95(3), 745\u2013755 (2000).","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"2","key":"93024_CR9","doi-asserted-by":"publisher","first-page":"100397","DOI":"10.1016\/j.modpat.2023.100397","volume":"37","author":"S Loghavi","year":"2024","unstructured":"Loghavi, S. et al. Of the world health classification of tumors of the hematopoietic and lymphoid tissue: Myeloid neoplasms. Mod. Pathol. 37(2), 100397 (2024).","journal-title":"Mod. Pathol."},{"key":"93024_CR10","unstructured":"CEBPA Gene Card Page. Available from https:\/\/www.genecards.org\/cgi-bin\/carddisp.pl?gene=CEBPA&keywords=CEBPA. Accessed May 2022."},{"issue":"4","key":"93024_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/bjh.16534","volume":"190","author":"AS Wilhelmson","year":"2020","unstructured":"Wilhelmson, A. S. & Porse, B. T. CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: Cooperating lesions, molecular mechanisms and clinical relevance. Br. J. Haematol. 190(4), 495\u2013507 (2020).","journal-title":"Br. J. Haematol."},{"key":"93024_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/ijlh.13517","volume":"43","author":"H Mendoza","year":"2021","unstructured":"Mendoza, H., Podoltsev, N. A. & Siddon, A. J. Laboratory evaluation and prognostication among adults and children with CEBPA-mutant acute myeloid leukemia. Int. J. Lab. Hematol. 43, 86\u201395 (2021).","journal-title":"Int. J. Lab. Hematol."},{"issue":"4","key":"93024_CR13","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1182\/blood-2003-02-0477","volume":"102","author":"K Keeshan","year":"2003","unstructured":"Keeshan, K. et al. Transcription activation function of C\/EBP\u03b1 is required for induction of granulocytic differentiation. Blood 102(4), 1267\u20131275 (2003).","journal-title":"Blood"},{"issue":"4","key":"93024_CR14","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/leu.2013.273","volume":"28","author":"A Fasan","year":"2014","unstructured":"Fasan, A. et al. The role of different genetic subtypes of CEBPA mutated AML. Leukemia 28(4), 794\u2013803 (2014).","journal-title":"Leukemia"},{"issue":"2","key":"93024_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1179\/1607845412Y.0000000032","volume":"18","author":"MM Awad","year":"2013","unstructured":"Awad, M. M. et al. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: Impact on prognosis. Hematology 18(2), 61\u201368 (2013).","journal-title":"Hematology"},{"issue":"10","key":"93024_CR16","first-page":"1214","volume":"126","author":"K Tawana","year":"2015","unstructured":"Tawana, K. et al. Disease evolution and outcomes in Familial AML with germline CEBPA mutations. Blood J. Am. Soc. Hematol. 126 (10), 1214\u20131223 (2015).","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"8","key":"93024_CR17","first-page":"2469","volume":"117","author":"E Taskesen","year":"2011","unstructured":"Taskesen, E. et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: Further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood J. Am. Soc. Hematol. 117 (8), 2469\u20132475 (2011).","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"2","key":"93024_CR18","first-page":"136","volume":"7","author":"M Gholami","year":"2019","unstructured":"Gholami, M. et al. Investigation of CEBPA and CEBPA-AS genes expression in acute myeloid leukemia. Rep. Biochem. Mol. Biol. 7(2), 136 (2019).","journal-title":"Rep. Biochem. Mol. Biol."},{"issue":"12","key":"93024_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s12032-020-01436-z","volume":"37","author":"A Krygier","year":"2020","unstructured":"Krygier, A. et al. Association between the CEBPA and c-MYC genes expression levels and acute myeloid leukemia pathogenesis and development. Med. Oncol. 37(12), 109 (2020).","journal-title":"Med. Oncol."},{"key":"93024_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-019-1944-x","volume":"17","author":"K Li","year":"2019","unstructured":"Li, K. et al. CEBPE expression is an independent prognostic factor for acute myeloid leukemia. J. Transl. Med. 17, 1\u201311 (2019).","journal-title":"J. Transl. Med."},{"key":"93024_CR21","unstructured":"DNMT3A Gene Card Page. Available from https:\/\/www.genecards.org\/cgi-bin\/carddisp.pl?gene=DNMT3A&keywords=DNMT3A. Accessed May 2022."},{"issue":"3","key":"93024_CR22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/nrc3895","volume":"15","author":"L Yang","year":"2015","unstructured":"Yang, L., Rau, R. & Goodell, M. A. DNMT3A in haematological malignancies. Nat. Rev. Cancer 15(3), 152\u2013165 (2015).","journal-title":"Nat. Rev. Cancer"},{"issue":"14","key":"93024_CR23","doi-asserted-by":"publisher","first-page":"14677","DOI":"10.18632\/aging.103520","volume":"12","author":"TJ Zhang","year":"2020","unstructured":"Zhang, T. J. et al. Expression and prognosis analysis of DNMT family in acute myeloid leukemia. Aging 12(14), 14677 (2020).","journal-title":"Aging"},{"key":"93024_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43042-020-00066-4","volume":"21","author":"IA Asfour","year":"2020","unstructured":"Asfour, I. A. et al. Prognostic significance of DNMT3a gene expression and reactive nitrogen species in newly diagnosed Egyptian de Novo adult acute myeloid leukemia patients. Egypt. J. Med. Hum. Genet. 21, 1\u201316 (2020).","journal-title":"Egypt. J. Med. Hum. Genet."},{"issue":"1","key":"93024_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5045\/br.2020.55.1.17","volume":"55","author":"DJ Park","year":"2020","unstructured":"Park, D. J. et al. Characteristics of DNMT3A mutations in acute myeloid leukemia. Blood Res. 55 (1), 17 (2020).","journal-title":"Blood Res."},{"key":"93024_CR26","doi-asserted-by":"publisher","first-page":"628248","DOI":"10.3389\/fonc.2021.628248","volume":"11","author":"X Xu","year":"2021","unstructured":"Xu, X. et al. Prognostic nomogram for acute myeloid leukemia patients with biallelic CEBPA mutations. Front. Oncol. 11, 628248 (2021).","journal-title":"Front. Oncol."},{"issue":"4","key":"93024_CR27","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/cas.15720","volume":"114","author":"S Wakita","year":"2023","unstructured":"Wakita, S. et al. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia. Cancer Sci. 114(4), 1297\u20131308 (2023).","journal-title":"Cancer Sci."},{"issue":"6","key":"93024_CR28","doi-asserted-by":"publisher","first-page":"e281","DOI":"10.1016\/j.clml.2019.02.001","volume":"19","author":"MM El Gammal","year":"2019","unstructured":"El Gammal, M. M. et al. Clinical effect of combined mutations in DNMT3A, FLT3-ITD, and NPM1 among Egyptian acute myeloid leukemia patients. Clin. Lymphoma Myeloma Leuk. 19(6), e281\u2013e290 (2019).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"2","key":"93024_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41375-024-02140-x","volume":"38","author":"JA Georgi","year":"2024","unstructured":"Georgi, J. A. et al. Prognostic impact of CEBPA mutational subgroups in adult AML. Leukemia 38(2), 281\u2013290 (2024).","journal-title":"Leukemia"},{"issue":"12","key":"93024_CR30","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/gtc.12102","volume":"18","author":"J Xu","year":"2013","unstructured":"Xu, J., Kawai, Y. & Arinze, I. J. Dual role of C\/EBP \u03b1 as an activator and repressor of G\u03b1i2 gene transcription. Genes Cells 18(12), 1082\u20131094 (2013).","journal-title":"Genes Cells"},{"issue":"3","key":"93024_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jnci.2013.02.002","volume":"25","author":"N Kassem","year":"2013","unstructured":"Kassem, N. et al. CCAAT\/enhancer binding protein \u03b1 gene expression in Egyptian patients with acute myeloid leukemia. J. Egypt. Natl. Cancer Inst. 25(3), 115\u2013120 (2013).","journal-title":"J. Egypt. Natl. Cancer Inst."},{"issue":"23","key":"93024_CR32","doi-asserted-by":"publisher","first-page":"14789","DOI":"10.1073\/pnas.232568499","volume":"99","author":"VI Rebel","year":"2002","unstructured":"Rebel, V. I. et al. Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc. Natl. Acad. Sci. 99(23), 14789\u201314794 (2002).","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"93024_CR33","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1101\/gad.14.3.272","volume":"14","author":"AL Kung","year":"2000","unstructured":"Kung, A. L. et al. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev. 14(3), 272\u2013277 (2000).","journal-title":"Genes Dev."},{"issue":"9","key":"93024_CR34","first-page":"2771","volume":"93","author":"Y Oike","year":"1999","unstructured":"Oike, Y. et al. Mice homozygous for a truncated form of CREB-binding protein exhibit defects in hematopoiesis and vasculo-angiogenesis. Blood J. Am. Soc. Hematol. 93(9), 2771\u20132779 (1999).","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"9","key":"93024_CR35","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.leukres.2008.01.007","volume":"32","author":"F D\u2019Al\u00f2","year":"2008","unstructured":"D\u2019Al\u00f2, F. et al. PU. 1 and CEBPA expression in acute myeloid leukemia. Leuk. Res. 32(9), 1448\u20131453 (2008).","journal-title":"Leuk. Res."},{"issue":"4","key":"93024_CR36","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/86515","volume":"7","author":"T Pabst","year":"2001","unstructured":"Pabst, T. et al. AML1\u2013ETO downregulates the granulocytic differentiation factor C\/EBP\u03b1 in t (8; 21) myeloid leukemia. Nat. Med. 7(4), 444\u2013451 (2001).","journal-title":"Nat. Med."},{"issue":"8","key":"93024_CR37","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1038\/bcj.2012.34","volume":"2","author":"V Grossmann","year":"2012","unstructured":"Grossmann, V. et al. Expression of CEBPA is reduced in RUNX1-mutated acute myeloid leukemia. Blood Cancer J. 2(8), e86 (2012).","journal-title":"Blood Cancer J."},{"issue":"6","key":"93024_CR38","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/ahg.12210","volume":"81","author":"F Salarpour","year":"2017","unstructured":"Salarpour, F. et al. Evaluation of CCAAT\/Enhancer binding protein (C\/EBP) alpha (CEBPA) and runt-related transcription factor 1 (RUNX1) expression in patients with de Novo acute myeloid leukemia. Ann. Hum. Genet. 81(6), 276\u2013283 (2017).","journal-title":"Ann. Hum. Genet."},{"issue":"3","key":"93024_CR39","first-page":"174","volume":"28","author":"SI Jung","year":"2008","unstructured":"Jung, S. I. et al. Two cases of trisomy 19 as a sole chromosomal abnormality in myeloid disorders. Korean J. Lab. Med. 28(3), 174\u2013178 (2008).","journal-title":"Korean J. Lab. Med."},{"issue":"3","key":"93024_CR40","first-page":"354","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade, D. et al. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the united Kingdom medical research Council trials. Blood. J. Am. Soc. Hematol. 116(3), 354\u2013365 (2010).","journal-title":"J. Am. Soc. Hematol."},{"issue":"5","key":"93024_CR41","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.cell.2009.06.049","volume":"138","author":"Z Wang","year":"2009","unstructured":"Wang, Z. et al. Genome-wide mapping of hats and HDACs reveals distinct functions in active and inactive genes. Cell 138(5), 1019\u20131031 (2009).","journal-title":"Cell"},{"key":"93024_CR42","doi-asserted-by":"publisher","first-page":"612880","DOI":"10.3389\/fonc.2020.612880","volume":"10","author":"VE Kennedy","year":"2020","unstructured":"Kennedy, V. E. & Smith, C. C. FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies. Front. Oncol. 10, 612880 (2020).","journal-title":"Front. Oncol."},{"issue":"4","key":"93024_CR43","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1088\/1361-6544\/aa6063","volume":"30","author":"M Dai","year":"2017","unstructured":"Dai, M. et al. Analysis of a diffuse interface model of multispecies tumor growth. Nonlinearity 30 (4), 1639 (2017).","journal-title":"Nonlinearity"},{"issue":"4","key":"93024_CR44","first-page":"619","volume":"125","author":"H Celik","year":"2015","unstructured":"Celik, H. et al. Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation. Blood J. Am. Soc. Hematol. 125(4), 619\u2013628 (2015).","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"1","key":"93024_CR45","doi-asserted-by":"publisher","first-page":"10968","DOI":"10.1038\/ncomms10968","volume":"7","author":"D Bararia","year":"2016","unstructured":"Bararia, D. et al. Acetylation of C\/EBP\u03b1 inhibits its granulopoietic function. Nat. Commun. 7(1), 10968 (2016).","journal-title":"Nat. Commun."},{"issue":"6","key":"93024_CR46","first-page":"592","volume":"46","author":"EK Ebrahim","year":"2016","unstructured":"Ebrahim, E. K. et al. FLT3 internal tandem duplication mutation, cMPL and CD34 expressions predict low survival in acute myeloid leukemia patients. Ann. Clin. Lab. Sci. 46(6), 592\u2013600 (2016).","journal-title":"Ann. Clin. Lab. Sci."},{"issue":"1","key":"93024_CR47","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3892\/ol.2013.1347","volume":"6","author":"X Huang","year":"2013","unstructured":"Huang, X. et al. Gene expression profiling of the DNMT3A R882 mutation in acute leukemia. Oncol. Lett. 6(1), 268\u2013274 (2013).","journal-title":"Oncol. Lett."},{"issue":"25","key":"93024_CR48","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley, T. J. et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363(25), 2424\u20132433 (2010).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"93024_CR49","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.3892\/or.2014.3078","volume":"31","author":"JZ Shen","year":"2014","unstructured":"Shen, J. Z. et al. Overexpression of microRNA-143 inhibits growth and induces apoptosis in human leukemia cells. Oncol. Rep. 31(5), 2035\u20132042 (2014).","journal-title":"Oncol. Rep."},{"issue":"2","key":"93024_CR50","first-page":"77","volume":"6","author":"AR Elhamamsy","year":"2017","unstructured":"Elhamamsy, A. R. et al. Circulating miR-92a, miR-143 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. Int. J. Mol. Cell. Med. 6(2), 77 (2017).","journal-title":"Int. J. Mol. Cell. Med."},{"issue":"5","key":"93024_CR51","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/ajh.21667","volume":"85","author":"G Cammarata","year":"2010","unstructured":"Cammarata, G. et al. Differential expression of specific MicroRNA and their targets in acute myeloid leukemia. Am. J. Hematol. 85(5), 331\u2013339 (2010).","journal-title":"Am. J. Hematol."},{"issue":"12","key":"93024_CR52","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.31557\/APJCP.2019.20.12.3625","volume":"20","author":"MM Gado","year":"2019","unstructured":"Gado, M. M. et al. Assessment of the diagnostic potential of miR-29a-3p and miR-92a-3p as circulatory biomarkers in acute myeloid leukemia. Asian Pac. J. cancer Prev. APJCP 20(12), 3625 (2019).","journal-title":"Asian Pac. J. cancer Prev. APJCP"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93024-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93024-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93024-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T12:06:31Z","timestamp":1757160391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93024-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["93024"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-93024-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"9 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to amend the license information.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent was obtained from all participants, and this study was approved by the NCI Institutional Review Board following the principles of the Declaration of Helsinki-approved protocol.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"12473"}}